OECD Trade Policy Papers

ISSN :
1816-6873 (en ligne)
DOI :
10.1787/18166873
Cacher / Voir l'abstract
This series is designed to make available to a wider readership selected trade policy studies prepared for use within the OECD.

NB. No. 1 to No. 139 were released under the previous series title OECD Trade Policy Working Papers.

 

Trade and Innovation: Pharmaceuticals You or your institution have access to this content

Anglais
Cliquez pour accéder: 
    http://oecd.metastore.ingenta.com/content/5kgdscrcv7jg.pdf
  • PDF
  • http://www.keepeek.com/Digital-Asset-Management/oecd/trade/trade-and-innovation-pharmaceuticals_5kgdscrcv7jg-en
  • LIRE
Auteur(s):
Nobuo Kiriyama1
Author Affiliations
  • 1: OCDE, France

Date de publication
01 avr 2011
Bibliographic information
N°:
113
Pages
70
DOI
10.1787/5kgdscrcv7jg-en

Cacher / Voir l'abstract

Globalisation in the pharmaceuticals sector is entering a new phase. Many new drugs are marketed globally, and these revenues encourage further investment in research and development (R&D). The industry is undergoing substantial transition, with increased competition and downward pressure on prices. Moreover, there have also been widespread concerns that R&D productivity may be declining in recent years. This study examines how various linkages between trade and innovation work in the pharmaceuticals sector, focusing on the role of globalisation in the current innovation challenges of the pharmaceutical industry. It finds that emerging economies are increasingly important markets for pharmaceutical companies and more active participants in the R&D process. While this is an important part of an effort to reduce R&D costs and to improve R&D performance by established multinationals, this also contributes to upgrading the R&D capability of emerging economies. Various trade facilitating measures have been put in place at the international level, including tariff elimination under the World Trade Organization (WTO), plurilateral and bilateral regulatory harmonisation, mutual recognition and enforcement cooperation, and intellectual property protection. Given the growing participation of emerging economies in this sector, further involvement of emerging economies in these arrangements is likely to become more important to facilitate trade and globalisation of R&D.
Mots-clés:
emerging economies, tariff elimination, WTO, intellectual property, pharmaceutical innovation, regulatory harmonisation, globalisation of R&D, mutual recognition
Classification JEL:
  • F13: International Economics / Trade / Trade Policy; International Trade Organizations
  • F14: International Economics / Trade / Empirical Studies of Trade
  • L65: Industrial Organization / Industry Studies: Manufacturing / Chemicals; Rubber; Drugs; Biotechnology
  • O31: Economic Development, Technological Change, and Growth / Technological Change; Research and Development; Intellectual Property Rights / Innovation and Invention: Processes and Incentives